We hear the word whispered from a friend or family member, thereupon thinking, “I’m glad it’s not me.” Cancer. Not the automatic death sentence the word once represented, moreover, with today’s technology, early detection is common, cancer treatment options have expanded, chances are someone we know is a survivor.
Eric Lefkofsky’s Tempus, founded in Chicago in 2015, sails on the leading edge in engaging clinical data for cancer care, his startup receiving $80 million in new investment in March, total outside investment amounting to $210 million in the last three years. A 400-employee company, hiring at a rapid rate, Tempus valuation over $1 billion, the company continues to expand its reach.
During his years with Groupon, a company Eric Lefkofsky co-founded, he and his wife frequently donated to cancer research through their own Lefkofsky Family Foundation. Accordingly, Eric’s philanthropic interest attracted the attention of historic Lurie Children’s Hospital in Chicago where he became a Trustee. U.S. News & World Report recently recognized Lurie, a large pediatric research and treatment facility, with inclusion on its ‘Best Children’s Hospitals Honor Roll’.
Typically, cancer clinical data are abundant, frequently spread out among multiple repositories: plain paper files, hospital, and clinic databases, other unconnected, marginally searchable digital sources. The concept behind Tempus, thought Eric, was to utilize data collection, imagining one searchable mega-library, to permit clinicians and researchers to share information, allowing a level of collaboration never before possible. Consequently, after three years, Tempus can state it is building “the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful.”
Having molecular data about cancerous tumors, in addition to clinical data from cancer treatment aids physicians and researchers in the analysis of trends, subsequently enabling more effective patient treatment. As Eric explains, this vast trove of searchable knowledge, “… will allow us to truly personalize the drugs and therapies for each patient… We can keep them alive longer.”
New Enterprise Associates and Revolution Growth were major investors, joined by Kinship Trust and T. Rowe Price.
Contact Eric Lefkofsky: www.crunchbase.com/person/eric-lefkofsky